Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06531811 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06531811: Completed Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
NCT06531811 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 32 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06531811, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the potential difference between pharmacokinetics (PK), safety, tolerability and device performance between the AZD8630 test formulation and the AZD8630 reference formulation.
Primary Outcome
To evaluate the relative bioavailability of AZD8630 test device compared to AZD8630 Monodose device.
Conditions Studied
Interventions
- DRUG AZD8630 (test formulation) via test inhaler
- DRUG AZD8630 (reference formulation) via Monodose inhaler
- DEVICE Test inhaler
- DEVICE Monodose inhaler
Study Locations (1)
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2024-10-03 |
| Phase | Phase 1 |
What the finished NCT06531811 record still lists
NCT06531811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 4 interventions - of which AZD8630 (test formulation) via test inhaler is the first listed.
NCT06531811 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06531811 about?
NCT06531811 is a clinical study titled "A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.". The purpose of this study is to evaluate the potential difference between pharmacokinetics (PK), safety, tolerability and device performance between the AZD8630 test formulation and the AZD8630 reference formulation.
What is the current status of trial NCT06531811?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-08-06. Estimated completion is 2024-10-03.
What conditions does trial NCT06531811 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06531811?
The interventions under investigation include: AZD8630 (test formulation) via test inhaler (DRUG), AZD8630 (reference formulation) via Monodose inhaler (DRUG), Test inhaler (DEVICE), Monodose inhaler (DEVICE).
Who is sponsoring clinical trial NCT06531811?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06531811 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06531811's enrollment target sits among peer trials
32 66th of 119 higher than 51 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI